Kazia Therapeutics gets fast track status for paxalisib in glioblastoma

Kazia Therapeutics, an Australian oncology company, has secured fast track designation (FTD) from the US Food and Drug Administration (FDA) for paxalisib (formerly GDC-0084) for ... Read More